Exicure (NASDAQ:XCUR) Stock Price Down 0.8% – Here’s What Happened

Exicure, Inc. (NASDAQ:XCUR)’s stock price fell 0.8% during mid-day trading on Thursday. The stock traded as low as $1.2150 and last traded at $1.23. Approximately 22,873 shares were traded during mid-day trading, a decline of 38% from the average daily volume of 37,063 shares. The stock had previously closed at $1.24.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Exicure in a research note on Tuesday, September 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Exicure currently has an average rating of “Sell”.

Exicure Price Performance

The firm has a market cap of $8.06 million, a P/E ratio of -0.93 and a beta of 3.63. The firm’s 50-day moving average price is $1.42 and its 200 day moving average price is $2.59.

Exicure (NASDAQ:XCUR) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($18.60) by $18.42.

Exicure Company Profile

Exicure, Inc was a biotechnology company focused on developing therapeutics based on its spherical nucleic acid (SNA) technology. The company’s platform was designed to deliver nucleic acids into cells and tissues, with the goal of regulating disease-related genes and proteins.

Exicure’s research programs addressed conditions in dermatology, immunology and other therapeutic areas. Its development portfolio included candidates such as AST-005, an SNA-based therapy investigated for psoriasis, along with programs targeting inflammatory and genetic diseases.